📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. (2020)

First Author: Greenland JC

Attributed to: The NET-PDD study: defining the roles of NEuroinflammation and Tau aggregation in Parkinson's Disease Dementia funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2020-040527

PubMed Identifier: 33234645

Publication URI: http://europepmc.org/abstract/MED/33234645

Type: Journal Article/Review

Volume: 10

Parent Publication: BMJ open

Issue: 11

ISSN: 2044-6055